Science

Feb 22, 2025, 14:10

Yan Leyfman: Advancing CAR T-Cell Therapy – Off-the-Shelf Allogeneic Approach

Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Frederick Locke et al. published in the Journal of Clinical Oncology:

“Advancing CAR T-Cell Therapy: Off-the-Shelf Allogeneic Approach.

The ALPHA/ALPHA2 studies evaluated the allogeneic CD19 CAR T-cell product cema-cel in relapsed/refractory large B-cell lymphoma (R/R LBCL) – offering a potential off-the-shelf alternative to autologous CAR T-cell therapy.

Key Findings:

Promising efficacy: 58% overall response rate (ORR), 42% complete response rate (CRR)
CAR T expansion observed post-infusion, with persistence up to 4 months
Manageable safety profile: No cases of GVHD, ICANS, or grade ≥3 CRS
Median duration of CR: 23.1 months

These results highlight cema-cel’s potential to improve accessibility and efficacy in LBCL treatment! Further studies are warranted to solidify its role in the next-gen immunotherapy landscape.”

“Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies”

Authors: Frederick Locke, Javier Munoz, Michael Tees, John Le Gall, Sattva Neelapu et al.

Yan Leyfman: Advancing CAR T-Cell Therapy - Off-the-Shelf Allogeneic Approach

More posts featuring Yan Leyfman.

cancer CAR T-cell therapy Frederick Locke Javier Munoz John Le Gall Michael Tees OncoDaily Oncology R/R LBCL relapsed/refractory large B-cell lymphoma Sattva Neelapu Yan Leyfman

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity